

Exercise of warrants of series T01

Polymer Factory Sweden AB



A World Leading Provider of
Dendritic Materials and Mass
Spectrometry Standards

Exercise period: 24 February – 17 March 2022

During the exercise period, holders of warrants of series T01 have the right to subscribe for shares in Polymer Factory Sweden AB. Upon full exercise of warrants of series T01, Polymer Factory will receive approximately SEK 5.2 million (before deduction of transaction related costs). The issue proceeds will mainly be used to finance an acceleration of the Company's sales and growth.

IMPORTANT INFORMATION – REFERENCE TO MEMORANDUM

This teaser is a marketing brochure prepared by Polymer Factory Sweden AB ("Polymer Factory", "PF" or the "Company") and does not constitute a memorandum. Readers are asked to read the memorandum published by Polymer Factory in February 2021 for a description of the risks associated with an investment in the Company. The Memorandum is available on the Company's (www.polymerfactory.com) and Spotlight Stock Market's (www.spotlightstockmarket.com) websites.



The offer in brief

Exercise period:

24 February – 17 March 2022.

Subscription price:

Each warrant of series TO1 gives the holder the right to subscribe for one (1) new share in Polymer Factory at a price of SEK 9.10.

Issue volume:

There are 568,066 outstanding warrants of series TO1. Upon full exercise of warrants of series TO1, Polymer Factory will receive approximately SEK 5.2 million before deduction of transaction related costs.

Last day of trading in warrants:

15 March 2022.

Number of outstanding shares in Polymer Factory:

6,859,198 shares.

Valuation in the current offer:

Approx. SEK 62.4 million.

The way forward and use of the proceeds

Since the successful IPO in April 2021, Polymer Factory has achieved its operational objectives (a selection is presented below). The focus ahead is to accelerate Polymer Factory's growth by recruiting key personnel with expertise in sales, increasing marketing activities, and expanding the Company's offering to the market. In 2022, the Company will launch its new DNG technology, aiming at increasing sources of income for Polymer Factory, possibly attracting more customers, and making the Company reach new product segments. Furthermore, the launch of Polymer Factory's technological platform BowtieD[®] and enhancements of the mass spectrometry instrument SpheriCal[®] creates income opportunities for the Company's long- and short-term growth. Polymer Factory increased its sales by 66 percent during the first three quarters during 2021 compared to 2020 – a figure that the Company intends to exceed in the coming year.

If all warrants of series TO1 are exercised, the Company will receive net proceeds of approximately SEK 4.7 million. This will finance the following activities:

- Approx. 80-90% will be used to accelerate sales and match the need of customers by recruiting key personnel with expertise in sales, increasing marketing activities, and expanding the Company's offering to the market.
- Approx. 5-10% for maintenance and expansion of IP rights for the Company's patent portfolio.
- Approx. 10-20% will, as the products have scale-up potential in regulatory stringent markets i.e., MedTech, BioTech, etc., be used to actively pursue necessary accreditations including quality management system (QMS) and other ISOs.

Completed milestones and events since the IPO



Partnership with OEM



Increase sales of SpheriCal[®]



Increase sales of dendritic amplifiers



Increased portfolio of dendritic amplifiers



Secure an NDA with at least one company for dendritic amplifiers



At least one R&D project with a global company



Hire a Production Manager Analytical Materials



Hire a Production Manager DNG



Secure a new lab



Launch of new product platform BowtieD[®].



Hire a new CEO



Continue the intellectual property rights protection of the DNG technology

CEO Elin Mignérus comments

Since the listing on Spotlight Stock Market in April 2021, Polymer Factory has delivered by its operational objectives, and we are now heading out to increase sales by expanding the Company's offering to the market. We have created a solid foundation for increased sales and growth in the past year, and we are well positioned to enter 2022.

Following the listing on Spotlight Stock Market, we have had a particularly productive year and Polymer Factory has delivered in accordance with its operational objectives communicated in connection with the IPO. The obvious highlights are several major orders during 2021 and 2022, including one from a global life science player corresponding to approx. SEK 160,000 in January 2022. Purchases of these sizes are important for us because they create opportunities for future repurchases from the same customer later – a reoccurring pattern among other customers.

We have also extended our Quality Agreement with the re-seller Merck KGaA, which means that Merck now repurchases more SpheriCal® products than before. Merck KGaA is one of the world's largest chemical and pharmaceutical companies and the in-depth collaboration strengthens our distribution channels while creating increased international visibility for Polymer Factory's product portfolio. This is well in line with our long-term growth strategy and the goal of being the obvious choice for all actors in need of dendritic material for product development and research. SpheriCal® has been a certified brand in the USA, Japan, South Korea, and Australia since November 2021, this expands our opportunities to increase sales globally.

The core of Polymer Factory's business model is to establish long-term relationships and gradually increase our base of international customers, distributors, and partners. This is how we have been able to create a strong existing customer base consisting of, among others, Novartis, Sanofi, Illumina, Evonik, Bruker, JEOL, and Biomerieux. In the same way, we have been successful in establishing partnerships and collaborations with multinational corporations such as Covestro AG, Perstorp AB, and Creative Pegworks (CPW). We look forward to increasing our stock of customers, distributors, and partners in the upcoming years, contributing to our long-term business perspective, creating lasting and sustainable affairs.

In 2021, we increased our sales for the first three quarters by approx. 66 percent compared to 2020. To increase our revenues, we are creating new sources of income and expanding our product portfolio.

In the coming year, we look forward to launching and scaling up the Company's DNG technology. The DNGs can function as nanocarrier systems with potential use to encapsulate and control the release of pharmaceuticals, peptides, antibiotics, and more. Apart from being a highly usable innovation for businesses worldwide, this provides Polymer Factory with a new income source and further strengthens our offering to existing and future customers.

In 2022, we will also launch an expansion of our technology platform for SpheriCal® aimed at ESI and IM-MS. This advancement is moving us closer to becoming a full-service calibrant supplier in the MS market.

PF's market is spread over many industries, especially the pharmaceutical industry, MedTech, and BioTech, as well as the chemical and materials industries. Hence, the market potential is extensive and difficult to calculate when changes in each sector continue to affect market outlooks. Nevertheless, PF assesses that the market potential in the nanomedicine sector alone amounts to approximately EUR 146 billion. The market potential for MS instruments amounts to approximately EUR 380 million. The launch of BowtieD® in late 2021 and the upcoming launch of DNGs during 2022 will increase our market potential extensively.

It is my strongest conviction that the future for Polymer Factory is going to be successful and I look forward to the work that lies ahead: To accelerate our business by launching DNG, further develop our offering regarding SpheriCal® and launch a new segment of next-generation precision dendrimers – BowtieD®. We welcome everyone who wants to be part of our journey to exercise your warrants of series TO1. The proceeds will mainly be used to finance an acceleration of PF's sales by recruiting key personnel with expertise in sales, increasing marketing activities, and expanding the Company's offering to the market. We have come a long way, and there is a great potential left to realize. I hope you want to join us. Together we can take Polymer Factory to the next level.

"In 2021, we increased our sales for the first three quarters by approx. 66 percent compared to 2020. To increase our revenues, we are creating new sources of income and expanding our product portfolio."

Elin Mignérus - CEO Polymer Factory



Upcoming objectives

Launch and production scale-up of the Company's DNG technology

- A new way for Polymer Factory to attract more customers, increase sales and reach new product segments.
- The patent pending DNG (dendritic nanogel) technology is a new application of Polymer Factory's dendritic materials. By formulating the dendritic materials into nanogels, they can function as nanocarrier systems with potential use to encapsulate and control the release of pharmaceuticals, peptides, antibiotics, and more.

Secure ISO certificate 13485 (quality management system for medical devices) to advance the Company's operations in regulatory demanding sectors.

- Considering the highly regulated life science industry, obtaining the necessary certifications will position Polymer Factory better towards customers. For some customers, it is crucial that these regulatory steps are taken if they are to place orders on the Company's products.

2022

Secure at least one partnership agreement with Big Pharma, MedTech, or BioTech company with focus on dendritic amplifiers for product enhancement.

- Partnerships are intended to be long-lasting relationships where the customer/partner includes the dendritic amplifiers in their products. This could for example be to enhance a drug or vaccine. Continuous purchasing, scaling up, and supply agreements will positively impact Polymer Factory's long-term growth and revenue.

Launch of SpheriCal® ESI (Electrospray Ionization) and IM-MS (Ion Mobility Mass Spectrometry)

- Expanding the portfolio, the patented SpheriCal® platform beyond MADLI MS enables growth in the product segment. By adding calibrants for ESI and IM-MS, the Company can reach new customers and markets, and become a more full-service calibrant supplier in the MS markets.

Polymer Factory in short


A world leading provider of dendritic materials and mass spectrometry standards

Polymer Factory was founded in 2006 at KTH Royal Institute of Technology and has been essential in driving dendritic nanotechnology research to commercialization for almost 15 years – expertise that has been transferred to the Company's products. Emerging from many years of cutting-edge research within the field, Polymer Factory today has, in the board's assessment, the world's largest product portfolio of dendritic materials with customers ranging from BigPharma, MedTech- and BioTech-companies to research-intensive institutes and academic research groups. Polymer Factory has also used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed explicitly for Mass Spectrometry (MS) instruments.

What are dendritic materials?

Dendritic polymers act as smart delivery systems that enhance the effects of the substances they carry, e.g., a vaccine or an anticancer drug. Like trees with many branches, dendritic materials' architecture makes them unique and useful in a broad-ranging scenario. Thanks to their ability to repeat the exact same structure and maintain the

same properties, dendritic materials can be modified and attached based on specific needs. Typically, a substance is attached to the surface and/or internally in the dendritic body, enabling the dendritic macromolecule to carry, say, a cancer drug. Applications vary but show great promise, particularly in drug delivery (as it is possible to control e.g., drug release and increase circulation time in the body while decreasing the toxicity of the drugs), in diagnostics (customers may use the Company's material as a dendrimer-based surface, or biosensor, to better detect levels of a certain protein, e.g., antibodies), as a stabilizing component for RNA and DNA where they can play an important role in the development of vaccines, as well as in tissue engineering and treatment of infectious diseases (dendritic materials have displayed strong antibacterial properties and can improve the effectiveness of vaccines, providing stable and sustained release). Today, most pharmaceutical companies and others commonly use traditional carriers, for instance, liposomes and polymer-carriers that persistently display non-uniform masses and sizes – the Company's dendritic materials present a number of competitive advantages in relation to these, not the least in terms of consistency, high loading volumes, biocompatibility and a high degree of optimization.



Based on the Company's expertise in dendrimer production, Polymer Factory has also developed the patented calibration technology SpheriCal®, designed for MS instruments. Essentially, MS instruments measure the mass of material. Due to continuous changes in various system components, MS instruments require regular calibration with a set of known standards. SpheriCal® is therefore used as a high-performance calibrant to ensure the instruments do not provide misleading data.

BowtieD® - The next-generation platform for dendritic materials

At the end of 2021, Polymer Factory expanded its portfolio with a new platform of next generation dendritic materials under the trademark BowtieD®. These bifunctional dendrimers are extremely sophisticated materials that can carry two different functionalities on the surface. Bifunctional dendrimers have been explored as multi-purpose precision carriers for research in life science and biotechnology and have, for example, shown exceptional results as cancer drug carriers.

MARKET

Polymer Factory's dendritic nanotechnologies have the potential of accelerating innovation in material and life science sectors, particularly through the availability of precision dendritic products that can enhance and amplify a desired property that is underperforming by the Company's customers, for example in diagnostics, by carrying colorants and enhancing detection of diseases, or in tissue engineering by contributing to improved tissue growth. There is also growing demand for accurate calibration to enable faster and more precise analysis of chemical and biological substances in water, food, commercial/industrial products, and biological samples from patients, while at the same time ensuring that sharper and more demanding regulations are met. With the proceeds from the warrant exercise the Company will develop and expand the business and sales organization to accelerate Polymer Factory's long-term growth.

Summary of terms and conditions of warrants of series T01

Terms for warrants of series T01 in brief

There are 568,066 outstanding warrants of series T01. The holder of warrants of series T01 has the right to subscribe for one (1) new share in Polymer Factory for each warrant held at a price of SEK 9.10 per share. Subscription of new shares in Polymer Factory, by exercise of warrants of series T01, can be made during February 24 – March 17, 2022. Subscription of new shares is made by cash payment no later than 5:00 p.m. CEST on March 17, 2022.

Action from you as a warrant holder is required – How to exercise your warrants of series T01

In order for your warrants not to expire worthless your action is required. You must apply for subscription of new shares, by exercise of warrants, no later than 5:00 p.m. CEST March 17, 2022, alternatively sell your warrants no later than March 15, 2022.

You can have your warrants registered in two ways:

1. In a securities custody account with a bank or other nominee (for example, Avanza or Nordnet), in an investment savings account (Sw. Investeringssparkonto) or endowment account (Sw. Kapitalförsäkring). Your warrants are then nominee registered.
2. In a VP-account (a VP-account starts with three zeros). Your warrants are then directly registered.

If your warrants are nominee registered

Registered Subscription and payment of new shares, by exercise of warrants, shall be made to the account-holding bank/nominee with which the warrants are registered. The subscription and payment shall be made in accordance with instructions from each such bank or nominee. Usually, the bank/nominee sends out a digital notice to the account holder, otherwise it is enough to log into the securities custody account from the first day in the exercise period in order to get instructions on how to exercise warrants for subscription of new shares. If you do not find these instructions, please contact your bank or trustee. Please note that banks and other nominees

may set different time limits for the last day for subscription, hence it is recommended to contact the account-holding bank/nominee early in the exercise period. This folder will be sent out to most nominee registered warrant holders. Subscribed and paid for shares may be entered as “interim shares” or “IA” into your securities custody account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary shares in Polymer Factory.

If your warrants are directly registered

No VP-account statement will be sent out. Subscription of new shares, by exercise of warrants, shall be made by sending a completed subscription form to Nordic Issuing. In conjunction with sending the completed subscription form, payment must be made to Nordic Issuing in accordance with the payment details stated on the subscription form. Subscription form along with this folder will be sent to VP-account holders. Information containing a summary of the conditions for warrants of series T01 is available on www.sedermera.se and www.nordic-issuing.se. The detailed terms for the warrants are available in the article of associations of Polymer Factory which is publicly available and e.g. can be downloaded from the Company's website.

Subscription over EUR 15,000 where applicable

In the event that your subscription amounts to or exceeds EUR 15,000, money laundering forms must be completed and submitted to Nordic Issuing at the same time as payment is made according to the Swedish law (2017:630) on measures against money laundering and terrorist financing. Please note that interim shares cannot be delivered out even though payment has been received until the money laundering form has been approved by Nordic Issuing. Money laundering forms are available from Nordic Issuing.

Important dates for warrants of series T01



NOTE – In order for your warrants not to expire worthless, you must actively subscribe and pay for shares no later than 5:00 p.m. CEST March 17, 2022, alternatively sell your warrants no later than March 15, 2022.